Summary

Eligibility
for people ages 12 years and up (full criteria)
Location
at Costa Mesa, California and other locations
Dates
study started
completion around

Description

Summary

This phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy with atezolizumab may work better than combination chemotherapy alone in treating patients with colon cancer.

Official Title

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Details

Keywords

Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v8, Colonic Neoplasms, Hereditary Nonpolyposis Colorectal Neoplasms, Dietary Calcium, Leucovorin, Folic Acid, Oxaliplatin, Fluorouracil, Atezolizumab, Calcium, Monoclonal Antibodies, Levoleucovorin, Biospecimen Collection, Computed Tomography, Leucovorin Calcium, Magnetic Resonance Imaging, Quality-of-Life Assessment

Eligibility

Locations

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
ID
NCT02912559
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 700 study participants
Last Updated